2. Academic Validation
  3. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo

Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo

  • Antiviral Res. 2011 Jan;89(1):26-34. doi: 10.1016/j.antiviral.2010.11.002.
Jinhong Chang 1,  Wouter Schul,  Terry D Butters,  Andy Yip,  Boping Liu,  Anne Goh,  Suresh B Lakshminarayana,  Dominic Alonzi,  Gabriele Reinkensmeier,  Xiaoben Pan,  Xiaowang Qu,  Jessica M Weidner,  Lijuan Wang,  Wenquan Yu,  Nigel Borune,  Mark A Kinch,  Jamie E Rayahin,  Robert Moriarty,  Xiaodong Xu,  Pei-Yong Shi,  Ju-Tao Guo,  Timothy M Block
Affiliations

Affiliation

  • 1 Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, 3805 Old Easton Road, Doylestown, PA 18902, United States. jinhong.chang@drexelmed.edu
PMID: 21073903 DOI: 10.1016/j.antiviral.2010.11.002
Abstract

Cellular α-glucosidases I and II are Enzymes that sequentially trim the three terminal glucoses in the N-linked oligosaccharides of viral envelope glycoproteins. This process is essential for the proper folding of viral glycoproteins and subsequent assembly of many enveloped viruses, including Dengue virus (DENV). Imino sugars are substrate mimics of α-glucosidases I and II. In this report, we show that two oxygenated alkyl imino sugar derivatives, CM-9-78 and CM-10-18, are potent inhibitors of both α-glucosidases I and II in vitro and in treated Animals, and efficiently inhibit DENV Infection of cultured human cells. Pharmacokinetic studies reveal that both compounds are well tolerated at doses up to 100mg/kg in rats and have favorable pharmacokinetic properties and bioavailability in mice. Moreover, we showed that oral administration of either CM-9-78 or CM-10-18 reduces the peak viremia of DENV in mice. Interestingly, while treatment of DENV infected mice with ribavirin alone did not reduce the viremia, combination therapy of ribavirin with sub-effective dose of CM-10-18 demonstrated a significantly enhanced Antiviral activity, as indicated by a profound reduction of the viremia. Our findings thus suggest that combination therapy of two broad-spectrum Antiviral agents may provide a practically useful approach for the treatment of DENV Infection.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z